Ticker

NORCROSS, Ga., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced participation in the upcoming AASLD Liver Meeting 2026. The Company will deliver three presentations, including an oral presentation, a Poster of Distinction presentation, and one poster presentation, highlighting new risk analyses on…

NORCROSS, Ga., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that company management will present and attend the H.C.

SQZ Biotechnologies (NYSE: SQZ - Get Free Report) and Galectin Therapeutics (NASDAQ: GALT - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability and risk. Profitability This table compares SQZ Biotechnologies and

Certain stocks are such poor bets that they are likely to lose ground even in bull markets.

Galectin Therapeutics Inc. (NASDAQ: GALT - Get Free Report) shares passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $3.04 and traded as high as $4.21. Galectin Therapeutics shares last traded at $4.15, with a volume of 291,096 shares. Wall Street Analysts Forecast Growth A number